About Actinium Pharmaceuticals
Actinium Pharmaceuticals is a publicly listed company based in New York (United States) founded in 2000. Radiation conjugate antibodies are developed for cancer treatment. It operates on a HealthTech model. The company has 37 employees. Actinium Pharmaceuticals offers products and services including Actimab-A, ATNM-400, Iomab-ACT, and Iomab-B. Its focus areas include Biotechnology and Radiopharmaceuticals. Its legal entity is Actinium Pharmaceuticals, Inc. Its competitors include Ultragenyx, Regeneron Pharmaceuticals and Sutro Biopharma; 2 of its 3 listed competitors have raised funding.
Company details
Actinium Pharmaceuticals, Inc. is engaged in the development of targeted radiotherapies for patients with unmet medical needs. The company operates in the healthcare sector, specifically within biotechnology, focusing on radiopharmaceutical solutions. Products such as Actimab-A for AML, ATNM-400 for prostate cancer, and Iomab-ACT for gene and cell therapy conditioning are developed. Additionally, Actinium-225 manufacturing technology is utilized to support its therapeutic pipeline. Research and development efforts are directed toward innovative cancer treatments.
- Headquarters New York, United States
- Employees 37
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website actiniumpharma.com
- Social LinkedIn X
- Legal Name Actinium Pharmaceuticals, Inc. (Delaware)
- Annual Revenue$90 K (USD)as on Dec 31, 2025
- Net Profit-$33.89 M (USD)11.39as on Dec 31, 2025
- EBITDA-$35.43 M (USD)14.24as on Dec 31, 2025
- Latest Funding Round$2.11M (USD), Grant
Sep 2020
- Investors
- Employee Count37
Products & Services of Actinium Pharmaceuticals
Actinium Pharmaceuticals offers a comprehensive portfolio of products and services, including Actimab-A, ATNM-400, Iomab-ACT, and Iomab-B.
CD33 targeting therapeutic for r/r AML is developed.
First-in-class non-PSMA therapeutic for prostate cancer offered.
Conditioning solution for gene and cell therapy provided.
Targeted radiotherapy solution for specific conditions is developed.
Funding Insights of Actinium Pharmaceuticals
- Total Rounds 6
- Last Round Grant — $2.11M
- First Round $4.13M
(Oct 2011)
- Investors Count 1
All 6 funding rounds of Actinium Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $2.11M | Grant | – | – | |
| Jun 2015 | $5M | Post-IPO | – | – | – |
| Jan 2014 | $6.64M | Post-IPO | – | – | – |
| Dec 2012 | Post-IPO | – | – | – | |
| Nov 2011 | $364,000 | Post-IPO | – | – | – |
| Oct 2011 | $4.13M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Actinium Pharmaceuticals
Actinium Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Actinium Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Actinium Pharmaceuticals
25 people are tracked at Actinium Pharmaceuticals (17 in leadership, 4 in board & advisors, 4 in team); the tracked headcount is 37.
| Name | Role | Group |
|---|---|---|
Helen Kotanides | VP, Translational Research & Preclinical Development | Leadership |
Sandesh Seth | CEO & Chairman | Leadership |
Mojisola R. | Director Clinical Operations | Leadership |
Jennifer Spross | Director, Clinical Operations | Leadership |
Madhuri Vusirikala | VP, Clinical Development BMT & Cellular Therapy | Leadership |
Jenny Hsieh | Chief Strategy Officer | Leadership |
Gary Siegel | VP, Controller | Leadership |
Mary Mei Chen | VP, Clinical Development | Leadership |
Steve O'Loughlin | CFO | Leadership |
Monideepa Roy | VP, Corporate Development, R&D | Leadership |
Lynn Bodarky | Chief Business Officer | Leadership |
Jenny H. | Chief Strategy Officer | Leadership |
Garth Parham | Associate Director Business Development | Leadership |
Sara Miao | Director Of Project Management & Medical Affairs | Leadership |
Gajanan Dewkar | Director, Radiopharmaceutical Product Development | Leadership |
Adrian Hackett | Associate Director Preclinical Toxicology | Leadership |
Andrew Olsen | Associate Director Business Development | Leadership |
C. David Nicholson | Lead Independent Director | Board & advisors |
Richard I. Steinhart | Director | Board & advisors |
Ajit Shetty | Director | Board & advisors |
5 more people are available in the full profile.
Complete people profiles for Actinium Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Actinium Pharmaceuticals
Actinium Pharmaceuticals is a publicly listed company on the AMEX with ticker symbol ATNM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Jun 2011
- Listed onNYSE: ATNM
- Listed entityActinium Pharmaceuticals, Inc. (Delaware)
- Exchange sectorHealth technology
- ISINUS00507W2061
- Share price$1.00 (-5.71% on the day) · 2026-10-13
- Market capitalisation$31.4M
- Price to earnings2.8
- EPS (diluted, trailing year)$0.36
- Volume (last session)89,251
Financials of Actinium Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $90,000 | -$33.9M | -$35.4M |
| 2024 | -$38.2M | -$41.3M | |
| 2023 | $81,000 | -$48.8M | -$51.1M |
| 2022 | $930,000 | -$33.0M | -$33.5M |
| 2021 | $1.1M | -$24.8M | -$24.4M |
Detailed financial statements for Actinium Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Actinium Pharmaceuticals
4 dated milestones of Actinium Pharmaceuticals across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Actinium Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $4.1M.
- Funding Latest funding round, Grant, of $2.1M.
Competitors of Actinium Pharmaceuticals
Actinium Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Ultragenyx, Regeneron Pharmaceuticals and Sutro Biopharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| regeneron.com | 1988 | Tarrytown, United States | 13,450 | Antibodies are developed for treating cancer, eye, and inflammatory diseases. | ||
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. |
Detailed competitors of Actinium Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Actinium Pharmaceuticals
The website of Actinium Pharmaceuticals (actiniumpharma.com) receives about 6.2K visits a month and ranks #3,668,195 among all websites worldwide, #4,706 in Biotechnology and Pharmaceuticals.
- Monthly visits6.2K
▲ 21.3% vs previous month
- Unique visitors2.2K
per month
- Global rank#3,668,195
among all websites
- Category rank#4,706
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.8
- Average visit53 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with Actinium Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
catabasis.com | catabasis.com | 100% | – | ||
| athersys.com | 97% | 1.7K | #8,716,189 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Actinium Pharmaceuticals (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Actinium Pharmaceuticals
Complete news archive for Actinium Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Actinium Pharmaceuticals
Actinium Pharmaceuticals was founded in 2000 and raised its 1st funding round 11 years after it was founded.
Actinium Pharmaceuticals is headquartered in New York, United States. It is registered at New York, New York, United States.
Actinium Pharmaceuticals has 37 employees.
Annual revenue of Actinium Pharmaceuticals is $90K as on Dec 31, 2025.
Actinium Pharmaceuticals, Inc. is engaged in the development of targeted radiotherapies for patients with unmet medical needs. The company operates in the healthcare sector, specifically within biotechnology, focusing on radiopharmaceutical solutions. Products such as Actimab-A for AML, ATNM-400 for prostate cancer, and Iomab-ACT for gene and cell therapy conditioning are developed. Additionally, Actinium-225 manufacturing technology is utilized to support its therapeutic pipeline. Research and development efforts are directed toward innovative cancer treatments.
Actinium Pharmaceuticals's top competitors include Sutro Biopharma, Regeneron Pharmaceuticals and Ultragenyx.
Actinium Pharmaceuticals offers Actimab-A, ATNM-400, Iomab-ACT, and Iomab-B.
Yes, Actinium Pharmaceuticals is publicly traded on AMEX under the ticker symbol ATNM.
Actinium Pharmaceuticals has 1 investor. Key investors include HHS.
Actinium Pharmaceuticals operates through Actinium Pharmaceuticals, Inc..